過活動膀胱治療の世界市場-2022-2029

市場概要

過活動膀胱治療の世界市場規模は、予測期間（2022-2029年）にCAGR3.6％で成長すると予測されています。

過活動膀胱は、膀胱の壁が突然、不随意に筋収縮することを特徴とする排尿症候群の一群です。この結果、膀胱に少量の尿しか溜まっていないにもかかわらず、すぐに尿意を催し、それを抑えることが困難になります。このほか、夜間頻尿や尿失禁などの症状があります。

市場力学

過活動膀胱治療の世界市場を牽引する主な要因は、過活動膀胱の有病率の上昇、高齢者人口の増加、神経疾患や肥満の増加、主要な市場参加者による研究開発の増加などです。

研究開発投資の増加や技術的進歩の高まりは、市場の成長を促進すると期待されています。

過活動膀胱治療市場は、技術の進歩の高まり、老年人口の増加、研究開発投資の急増、過活動膀胱患者の増加、新興国の医療インフラにおける最新技術を用いた新規製品の改善によって牽引されています。

さらに、著名な主要市場関係者やメーカーは、革新的な作用機序を持つ神経筋遮断剤などの新薬や治療法を開発するために、継続的に新しい研究開発や投資の増加に取り組んでいます。投資と研究開発の増加は、市場の成長を後押しします。さらに、主要企業による技術的に高度な製品の提供も、市場の成長に重要な役割を果たすと予想されます。

これらの過活動膀胱治療薬に関する様々な新規製品の発売、調査研究、啓発活動の高まりは、市場の成長に寄与しています。例えば、2021年2月、アッヴィの傘下であるアラガン社は、抗コリン薬に耐えられない5歳以上の患者の神経症状に関連する起立性過活動（膀胱筋）に対して、同社のBOTOXを承認したと発表しています。

過活動膀胱治療に伴う副作用は、市場の成長を妨げると予想されます。

抗ムスカリン薬の使用後には、便秘、口渇、目のかすみ、尿路感染症、目のかゆみや乾燥、眠気、尿閉など、いくつかの副作用が認められます。時々、命にかかわるような不整脈を起こす人がいますが、その確率は非常にまれです。ドライマウスによる飲水は、過活動膀胱の症状を悪化させることがあります。

認知度の低さも、市場の成長を抑制する主要因となっています。低所得国では、人々は過活動膀胱の流行に気付いておらず、償還シナリオがないことが市場の成長を妨げています。

COVID-19の影響分析

パンデミックは、世界の財政的な期待、オペレーション、危機対応戦略にプラスの影響を与えています。COVID-19の発生は、ヘルスケア産業に深刻な影響を与えています。過活動膀胱治療市場は、COVIDにより莫大な利益を経験しました。COVID患者では、過活動膀胱などの膀胱に関連する問題も観察されました。COVIDは患者の膀胱に影響を及ぼしました。主要メーカーは、様々な研究および臨床試験を開始しました。様々な取り組み、製品の上市、コラボレーション、合併が世界中で行われており、市場の成長を後押ししています。例えば、2022年7月、ウロバント・サイエンス社は、欧州エリアにおける過活動膀胱治療のためのVibegronの商業化について、ピエールファーブル・メディカメント社とのライセンス契約を発表しました。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 研究開発投資の増加
    • 技術的進歩の高まり
  • 抑制要因
    • 過活動膀胱治療に伴う副作用
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• プライシング分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 治療タイプ別

• 神経刺激療法
  • 仙骨神経刺激
  • 経皮的脛骨神経刺激療法
• 行動的介入
  • 骨盤底筋のエクササイズ
  • 健康的な体重
  • バイオフィードバック
  • 膀胱トレーニング
  • その他
• 薬物療法
  • 抗コリン作用のある薬
    • オキシブチニン（ディトロパン）
    • トルテロジン（デトロール）
    • トルスピウム（サンクチュラXR）
    • フェソテロジン（トビアス）
    • ソリフェナシン（ベシケア）
    • ダリフェナシン（イナベレックス）
  • β3アドレナリン作動薬
    • ミラベグロン（ミルベトリク）
    • ビベグロン（ジェムテサ）
• 膀胱ボツリヌス毒素注射剤
• 手術
  • 人工括約筋手術
  • 膀胱増大術
  • 括約筋切除術

第8章 疾患タイプ別

• 特発性過活動膀胱
• 神経因性過活動膀胱

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク
• 注目の主要企業リスト

第11章 企業プロファイル

• Medtronic
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Teva Pharmaceutical Industries Limited
• AbbVie Inc.
• Accord Healthcare Inc.
• Laborie
• Macleods Pharmaceuticals Ltd
• Urovant Sciences

第12章 過活動膀胱の世界治療市場-DataM

Market Overview

The global overactive bladder treatment market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 3.6% during the forecast period (2022-2029).

An overactive bladder is a group of urinary syndromes characterized by sudden, involuntary muscle contraction in the wall of the urinary bladder. This results in an immediate, compelling need to urinate that is difficult to suppress, even though the bladder may only contain a small amount of urine. Other symptoms include nocturia or urinary incontinence.

Market Dynamics

The major factors driving the global overactive bladder treatment market are the rise in the prevalence of overactive bladder, growth in the geriatric population, an increase in neurological disorders and obesity, and an increase in R&D by major market players.

The increasing research and development investments and rising technological advancements are expected to drive the market's growth.

The overactive bladder treatment market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of overactive bladder patients and improvements in novel products using the latest technology in medical infrastructure in emerging markets.

Furthermore, prominent key market players and manufacturers are continuously working on new research and development and increasing investments to develop new drugs and therapies, such as neuromuscular blocking agents with innovative mechanisms of action. A rise in investment and R&D boost market growth. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives about these Overactive Bladder Treatments contribute to the market's growth. For instance, in February 2021, Allergan, a company of AbbVie, announced the approval of its BOTOX for detrusor overactivity (bladder muscle) related to the neurologic condition in patients aged five years or older who have intolerability to anticholinergic medicines.

Side effects associated with overactive bladder treatments are expected to hamper the market's growth.

Several side effects are observed after using antimuscarinic medicines, such as constipation, dry mouth, blurred vision, urinary tract infection, itchy or dry eyes, drowsiness and urinary retention. Sometimes people experience irregular heart rhythms that can be life-threatening, but their chances are very rare. Drinking water due to dry mouth can aggravate the overactive bladder symptoms.

Lack of awareness is also a leading factor restraining the market's growth. In low-income countries, people are unaware of overactive bladder prevalence, and the unavailability of reimbursement scenarios hinders the market's growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The overactive bladder treatment market has experienced huge profits due to COVID. In covid patients, bladder-related problems such as overactive bladder were also observed. COVID affected the bladders of patients. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in July 2022, Urovant Sciences announced its license agreement with Pierre Fabre Medicament for Vibegron commercialization for overactive bladder treatment in European Areas.

Segment Analysis

The nerve stimulation segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The nerve stimulation treatment segment is the highest market holder in the global overactive bladder treatment market. The global overactive bladder treatment market is segmented based on treatment type as nerve stimulation, behavioral intervention, medications, botulinum toxin injections and surgery. The nerve stimulation segment is the largest market shareholder due to its inherent advantages over other treatments, increasing technological advancements and novel product launches.

Neuromodulation or nerve stimulation is an effective way to treat an overactive bladder. An electrode is implanted under the skin to stimulate nerves with electricity around the bladder. The electric signals traveling from the bladder to the brain are blocked with electricity reducing the symptoms of an overactive bladder are blocked. These therapies are of two types: sacral neuromodulation and percutaneous tibial nerve stimulation.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in April 2021, Medtronic, the medical technology company, announced receiving approval from the United States Food and Drug Administration to continue the investigational device exemption trial for evaluating its implantable tibial neuromodulation device, an internally developed therapy specially developed for bladder incontinence symptom's relief.

Geographical Analysis

North America holds the largest market share in the global overactive bladder treatment market.

North America dominates the global overactive bladder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US and the growing geriatric population. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of overactive bladder medications and neurostimulation therapies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region contribute to the overactive bladder treatment market growth.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Jan 2021, Astellas Phrma Inc. announced its priority review acceptance by the United States Food and Drugs Administration for Mirabegron or Myrbetriq tablets, its novel drug application for neurogenic detrusor overactivity treatment in pediatric patients.

Competitive Landscape

The overactive bladder treatment market is highly competitive with local and global companies' presence. Medtronic, Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., Teva Pharmaceutical Industries Limited, AbbVie Inc., Accord Healthcare Inc., Laborie, Macleods Pharmaceuticals Ltd, Urovant Sciences and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in November 2022, Urovant Sciences, Sumitovant Biopharma Ltd's subsidiary, announced its partnership with Thinx Inc, an incontinence and period underwear brand. They launched "Time To Go," an educational campaign to educate people about overactive bladders, such as their symptoms and how to manage them.

Medtronic

Overview: Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Medtronic Bladder Control Therapy: This is a therapy in which the InterStim system delivers sacral neuromodulation. It utilizes an implantable device to deliver electrical pulses to sacral nerves near the tailbone hence creating miscommunication between sacral nerves and the brain to control the symptoms.

Key Development: In February 2022, Medtronic plc, a healthcare technology company, announced that its InterStim X got approved by the United States Food and Drug Administration. This new generation of InterStim recharge-free device is an advanced therapy system to provide sacral neuromodulation therapy for bowel and bladder incontinence,

The global overactive bladder treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing research and development investment
    • 4.1.1.2. Rising technological advancements
  • 4.1.2. Restraints:
    • 4.1.2.1. Side effects associated with overactive bladder treatments
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1 Porter's Five Forces Analysis
• 5.2 Supply Chain Analysis
• 5.3 Pricing Analysis
• 5.4 Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Nerve Stimulation *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.2.3. Sacral Nerve Stimulation
  • 7.2.4. Percutaneous Tibial Nerve Stimulation
• 7.3. Behavioural Intervention
  • 7.3.1. Pelvic Floor Muscle Exercise
  • 7.3.2. Healthy weight
  • 7.3.3. Biofeedback
  • 7.3.4. Bladder Training
  • 7.3.5. Others
• 7.4. Medication
  • 7.4.1. Anticholinergic medications
    • 7.4.1.1. Oxybutynin (Ditropan)
    • 7.4.1.2. Tolterodine (Detrol)
    • 7.4.1.3. Trospium (Sanctura XR)
    • 7.4.1.4. Fesoterodine (Toviaz)
    • 7.4.1.5. Solifenacin (Vesicare)
    • 7.4.1.6. Darifenacin (Enablex)
  • 7.4.2. Beta-3 adrenergic medication
    • 7.4.2.1. Mirabegron (Myrbetriq)
    • 7.4.2.2. Vibegron (Gemtesa)
• 7.5. Bladder Botulinum Toxin Injections
• 7.6. Surgery
  • 7.6.1. Artificial Sphincter Surgery
  • 7.6.2. Bladder Augmentation
  • 7.6.3. Sphincter Resection

8. By Disease Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.1.2. Market Attractiveness Index, By Disease Type
• 8.2. Idiopathic Overactive Bladder*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Neurogenic Overactive Bladder

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Products Benchmarking
• 10.4. List of Key Companies to Watch

11. Company Profiles

• 11.1. Medtronic *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Pfizer Inc.
• 11.3. Johnson & Johnson Services, Inc.
• 11.4. Astellas Pharma Inc.
• 11.5. Teva Pharmaceutical Industries Limited
• 11.6. AbbVie Inc.
• 11.7. Accord Healthcare Inc.
• 11.8. Laborie
• 11.9. Macleods Pharmaceuticals Ltd
• 11.10. Urovant Sciences

LIST NOT EXHAUSTIVE

12. Global Overactive Bladder Treatment Market - DataM

• 12.1. Appendix
• 12.2. About Us and Application
• 12.3. Contact Us